Fig. 1From: A phase Ib study of camrelizumab in combination with apatinib and fuzuloparib in patients with recurrent or metastatic triple-negative breast cancerTumor response. A Best percentage change in sum of diameters of the target lesion from baseline in individual patients. B Treatment duration and tumor response. Asterisk (*) symbol represents patients with a partial responseBack to article page